LabGenius
LabGenius operates the EVA™ platform, a highly automated discovery engine that uses machine learning to identify and co-optimise complex therapeutic antibodies. The company focuses on developing selectivity-enhanced antibodies for the treatment of solid tumours, specifically targeting multispecific antibody design. Its business model includes an internal drug pipeline and research collaborations with pharmaceutical partners for antibody development.
Visit websiteLondon, UK
Biotech
Artificial Intelligence
Healthcare
Pharmaceuticals
Funding summary
- Total raised
- €69.1M
- Funding rounds
- 4
Investors in LabGenius
Investors on record for LabGenius. Click any investor to view their CAPLINK profile and funding criteria.
Fundraising for a startup like LabGenius?
Explore CAPLINK's investor database of thousands of active VCs and angels.
Browse investors